The EDGE

New drug approvals in acute myeloid leukemia: what’s the best end point? OPEN

E Estey, M Othus, S J Lee, F R Appelbaum and R P Gale

Leukemia 2016 30: 521-525; advance online publication, December 18, 2015; 10.1038/leu.2015.262

Reviews

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives OPEN

S Lonial, B Durie, A Palumbo and J San-Miguel

Leukemia 2016 30: 526-535; advance online publication, August 12, 2015; 10.1038/leu.2015.223

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies

W Li, K Morrone, S Kambhampati, B Will, U Steidl and A Verma

Leukemia 2016 30: 536-544; advance online publication, October 26, 2015; 10.1038/leu.2015.297

Original Articles

ACUTE MYELOID LEUKEMIA

Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia

S Wakita, H Yamaguchi, T Ueki, K Usuki, S Kurosawa, Y Kobayashi, E Kawata, K Tajika, S Gomi, M Koizumi, Y Fujiwara, S Yui, K Fukunaga, T Ryotokuji, T Hirakawa, K Arai, T Kitano, F Kosaka, H Tamai, K Nakayama, T Fukuda and K Inokuchi

Leukemia 2016 30: 545-554; advance online publication, October 21, 2015; 10.1038/leu.2015.288

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia

C Müller-Tidow, P Tschanter, C Röllig, C Thiede, A Koschmieder, M Stelljes, S Koschmieder, M Dugas, J Gerss, T Butterfaß-Bahloul, R Wagner, M Eveslage, U Thiem, S W Krause, U Kaiser, V Kunzmann, B Steffen, R Noppeney, W Herr, C D Baldus, N Schmitz, K Götze, A Reichle, M Kaufmann, A Neubauer, K Schäfer-Eckart, M Hänel, R Peceny, N Frickhofen, M Kiehl, A Giagounidis, M Görner, R Repp, H Link, A Kiani, R Naumann, T H Brümmendorf, H Serve, G Ehninger, W E Berdel and U Krug for the Study Alliance Leukemia Group

Leukemia 2016 30: 555-561; advance online publication, November 2, 2015; 10.1038/leu.2015.306

CHRONIC MYELOGENOUS LEUKEMIA

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment OPEN

A Gratwohl, M Pfirrmann, A Zander, N Kröger, D Beelen, J Novotny, C Nerl, C Scheid, K Spiekermann, J Mayer, H G Sayer, C Falge, D Bunjes, H Döhner, A Ganser, I Schmidt-Wolf, R Schwerdtfeger, H Baurmann, R Kuse, N Schmitz, A Wehmeier, J Th Fischer, A D Ho, M Wilhelm, M-E Goebeler, H W Lindemann, M Bormann, B Hertenstein, G Schlimok, G M Baerlocher, C Aul, M Pfreundschuh, M Fabian, P Staib, M Edinger, M Schatz, A Fauser, R Arnold, T Kindler, G Wulf, A Rosselet, A Hellmann, E Schäfer, O Prümmer, M Schenk, J Hasford, H Heimpel, D K Hossfeld, H-J Kolb, G Büsche, C Haferlach, S Schnittger, M C Müller, A Reiter, U Berger, S Saußele, A Hochhaus and R Hehlmann for the SAKK and the German CML Study Group

Leukemia 2016 30: 562-569; advance online publication, October 14, 2015; 10.1038/leu.2015.281

CHRONIC LYMPHOCYTIC LEUKEMIA

Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo

B S Hanna, F McClanahan, H Yazdanparast, N Zaborsky, V Kalter, P M Rößner, A Benner, C Dürr, A Egle, J G Gribben, P Lichter and M Seiffert

Leukemia 2016 30: 570-579; advance online publication, November 2, 2015; 10.1038/leu.2015.305

LYMPHOMA

Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1

A E Teo, Z Chen, R N Miranda, T McDonnell, L J Medeiros and N McCarty

Leukemia 2016 30: 580-593; advance online publication, May 15, 2015; 10.1038/leu.2015.140

EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis OPEN

J Ma, K Nie, D Redmond, Y Liu, O Elemento, D M Knowles and W Tam

Leukemia 2016 30: 594-604; advance online publication, November 4, 2015; 10.1038/leu.2015.285

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas OPEN

P J Brown, K K Wong, S L Felce, L Lyne, H Spearman, E J Soilleux, L M Pedersen, M B Møller, T M Green, D M Gascoyne and A H Banham

Leukemia 2016 30: 605-616; advance online publication, October 26, 2015; 10.1038/leu.2015.299

A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma

A N Suhasini, L Wang, K N Holder, A-P Lin, H Bhatnagar, S-W Kim, A W Moritz and R C T Aguiar

Leukemia 2016 30: 617-626; advance online publication, October 27, 2015; 10.1038/leu.2015.302

MULTIPLE MYELOMA, GAMMOPATHIES

Search for familial clustering of multiple myeloma with any cancer

C Frank, M Fallah, T Chen, E K Mai, J Sundquist, A Försti and K Hemminki

Leukemia 2016 30: 627-632; advance online publication, October 9, 2015; 10.1038/leu.2015.279

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

G P Kaufman, M A Gertz, A Dispenzieri, M Q Lacy, F K Buadi, D Dingli, S R Hayman, P Kapoor, J A Lust, S Russell, R S Go, Y L Hwa, R A Kyle, S V Rajkumar and S K Kumar

Leukemia 2016 30: 633-639; advance online publication, October 21, 2015; 10.1038/leu.2015.287

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients

M A Frassanito, K De Veirman, V Desantis, L Di Marzo, D Vergara, S Ruggieri, T Annese, B Nico, E Menu, I Catacchio, R Ria, V Racanelli, M Maffia, E Angelucci, D Derudas, R Fumarulo, F Dammacco, D Ribatti, K Vanderkerken and A Vacca

Leukemia 2016 30: 640-648; advance online publication, October 21, 2015; 10.1038/leu.2015.289

MYELODYSPLASTIC SYNDROME

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

A M Zeidan, M A Sekeres, G Garcia-Manero, D P Steensma, K Zell, J Barnard, N A Ali, C Zimmerman, G Roboz, A DeZern, A Nazha, E Jabbour, H Kantarjian, S D Gore, J P Maciejewski, A List and R Komrokji on behalf of the MDS Clinical Research Consortium

Leukemia 2016 30: 649-657; advance online publication, October 14, 2015; 10.1038/leu.2015.283

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system

C Alhan, T M Westers, E M P Cremers, C Cali, B I Witte, G J Ossenkoppele and A A van de Loosdrecht

Leukemia 2016 30: 658-665; advance online publication, October 27, 2015; 10.1038/leu.2015.295

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

D A Sallman, R Komrokji, C Vaupel, T Cluzeau, S M Geyer, K L McGraw, N H Al Ali, J Lancet, M J McGinniss, S Nahas, A E Smith, A Kulasekararaj, G Mufti, A List, J Hall and E Padron

Leukemia 2016 30: 666-673; advance online publication, October 30, 2015; 10.1038/leu.2015.304

STEM CELL BIOLOGY

Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα

C Bueno, J L Sardina, B Di Stefano, D Romero-Moya, A Muñoz-López, L Ariza, M C Chillón, A Balanzategui, J Castaño, A Herreros, M F Fraga, A Fernández, I Granada, O Quintana-Bustamante, J C Segovia, K Nishimura, M Ohtaka, M Nakanishi, T Graf and P Menendez

Leukemia 2016 30: 674-682; advance online publication, October 26, 2015; 10.1038/leu.2015.294

Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia

S Geyh, M Rodríguez-Paredes, P Jäger, C Khandanpour, R-P Cadeddu, J Gutekunst, C M Wilk, R Fenk, C Zilkens, D Hermsen, U Germing, G Kobbe, F Lyko, R Haas and T Schroeder

Leukemia 2016 30: 683-691; advance online publication, November 25, 2015; 10.1038/leu.2015.325

STEM CELL TRANSPLANTATION

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation

T A Seldon, R Pryor, A Palkova, M L Jones, N D Verma, M Findova, K Braet, Y Sheng, Y Fan, E Y Zhou, J D Marks, T Munro, S M Mahler, R T Barnard, P D Fromm, P A Silveira, Z Elgundi, X Ju, G J Clark, K F Bradstock, D J Munster and D N J Hart

Leukemia 2016 30: 692-700; advance online publication, August 19, 2015; 10.1038/leu.2015.231

IMMUNOTHERAPY

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

K Pinz, H Liu, M Golightly, A Jares, F Lan, G W Zieve, N Hagag, M Schuster, A E Firor, X Jiang and Y Ma

Leukemia 2016 30: 701-707; advance online publication, November 3, 2015; 10.1038/leu.2015.311

MINIMAL RESIDUAL DISEASE

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

W Zeijlemaker, A Kelder, Y J M Oussoren-Brockhoff, W J Scholten, A N Snel, D Veldhuizen, J Cloos, G J Ossenkoppele and G J Schuurhuis

Leukemia 2016 30: 708-715; advance online publication, September 16, 2015; 10.1038/leu.2015.255

INFECTIOUS MEDICINE, VIROLOGY

A20 targets caspase-8 and FADD to protect HTLV-I-infected cells

Y Saitoh, A Hamano, K Mochida, A Kakeya, M Uno, E Tsuruyama, H Ichikawa, F Tokunaga, A Utsunomiya, T Watanabe and S Yamaoka

Leukemia 2016 30: 716-727; advance online publication, October 6, 2015; 10.1038/leu.2015.267

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

S Goyama, J Schibler, A Gasilina, M Shrestha, S Lin, K A Link, J Chen, S P Whitman, C D Bloomfield, D Nicolet, S A Assi, A Ptasinska, O Heidenreich, C Bonifer, T Kitamura, N N Nassar and J C Mulloy

Leukemia 2016 30: 728-739; advance online publication, October 9, 2015; 10.1038/leu.2015.275

Correspondence

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors’ reply

T Bernal, P Martínez-Camblor, J Sánchez-García and G Sanz

Leukemia 2016 30: 740-741; advance online publication, January 12, 2016; 10.1038/leu.2015.339

Letters To The Editor

MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia

D C de Leeuw, H J M P Verhagen, F Denkers, F G Kavelaars, P J M Valk, G J Schuurhuis, G J Ossenkoppele and L Smit

Leukemia 2016 30: 742-746; advance online publication, June 25, 2015; 10.1038/leu.2015.160

Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children OPEN

R Fu, D Liu, Z Cao, S Zhu, H Li, H Su, L Zhang, F Xue, X Liu, X Zhang, T Cheng, R Yang and L Zhang

Leukemia 2016 30: 746-749; advance online publication, June 29, 2015; 10.1038/leu.2015.167

Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice OPEN

K Hartmann, A Illing, F Leithäuser, A Baisantry, L Quintanilla-Martinez and K L Rudolph

Leukemia 2016 30: 749-753; advance online publication, July 2, 2015; 10.1038/leu.2015.173

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

H Wu, C Hu, A Wang, E L Weisberg, W Wang, C Chen, Z Zhao, K Yu, J Liu, J Wu, A Nonami, L Wang, B Wang, R M Stone, S Liu, J D Griffin, J Liu and Q Liu

Leukemia 2016 30: 754-757; advance online publication, July 3, 2015; 10.1038/leu.2015.175

Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia

P Ruminy, V Marchand, N Buchbinder, T Larson, B Joly, D Penther, E Lemasle, S Lepretre, E Angot, S Mareschal, P-J Viailly, S Dubois, F Clatot, M Viennot, E Bohers, D Rizzo, M Cornic, P Bertrand, C Girod, V Camus, P Etancelin, G Buchonnet, P Schneider, J-M Picquenot, J-P Vannier, C Bastard, H Tilly and F Jardin

Leukemia 2016 30: 757-760; advance online publication, July 3, 2015; 10.1038/leu.2015.177

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics

C Touzeau, J Ryan, J Guerriero, P Moreau, T N Chonghaile, S Le Gouill, P Richardson, K Anderson, M Amiot and A Letai

Leukemia 2016 30: 761-764; advance online publication, July 15, 2015; 10.1038/leu.2015.184